Diego Braguglia
General Partner @ VI Partners
Diego Braguglia is a Series B investor at VI Partners focused on Biotechnology and Health Care. Diego Braguglia joined VI Partners in January 2003 as a partner focusing on life-science and biotech investments. He brings over 10 years of experience in life science, medical devices and pharmaceuticals in Europe and the US. Prior to his entry into the VC industry Diego has held various managerial positions in the pharmaceuticals and medicaldevices sectors, as well as in biotech start ups in Europe and the US.Diego holds an M. Sc. in Microbiology from the Biocenter of the University of Basel and a Ph.D. in Molecular and Cellular Biology from the Swiss Cancer Research Institute (ISREC) in Lausanne. He is fluent in English, French Italian and German.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Diego Braguglia invests in
Stages Diego Braguglia invests in
Countries Diego Braguglia invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (33%)
- Health Care 3 (25%)
- Medical Device 3 (25%)
- Therapeutics 2 (17%)
- Biopharma 1 (8%)
Stage
- Series B 4 (33%)
- Series A 3 (25%)
- Series C 2 (17%)
Country
- Switzerland 5 (42%)
- Romania 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases. | $11.7M / Series A / Oct 08, 2024 | ||
| iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M / Series B / Jun 20, 2024 | ||
| iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $5.8M / Series A / Jul 14, 2020 | ||
| iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $16.5M / Series A / Jan 23, 2020 | ||
| Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $32.6M / Series B / Nov 12, 2018 | ||
| Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $9.5M / Series B / Sep 05, 2017 | ||
| Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology. | $3.1M / Series A / Mar 30, 2016 | ||
| Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $43.6M / Series C / Nov 27, 2013 | ||
| Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $40.3M / Series C / Nov 27, 2012 | ||
| Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Granted the CE mark in May 2009, Endosense's TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact forceduring the catheter ablation procedure. It has undergone considerable pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation. | $36M / Series B / Oct 27, 2009 | ||
| See all 12 investments → | |||
Co-Investors
About VI Partners
Healthcare & Technology Venture Capital since 2001
VI Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alain Nicod
Co-Founder and Managing Partner
|
|||
Arnd Kaltofen
Co-Founder and Managing Partner
|
|||
Cyrill Osterwalder
Principal
|
|||
|
Diego Braguglia
General Partner
|
|||
|
Olivier Laplace
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Diego Braguglia invest in?
Diego Braguglia invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series B and Series A stage. Most of the 12 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Diego Braguglia?
Public channels for Diego Braguglia include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Diego Braguglia last invest?
The most recent investment recorded for Diego Braguglia closed in Oct 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
